The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: The novel coronavirus disease (COVID-19) is caused by a new strain (SARS-CoV-2) that erupted in 2019. Nowadays, it is a great threat that claims uncountable lives worldwide. There is no specific chemotherapeutics developed yet to combat COVID-19. Therefore, scientists have been devoted to the quest of the medicine that can cure COVID-19.
OBJECTIVE: Existing antivirals, such as ASC09/ritonavir, lopinavir/ritonavir with or without umifenovir in combination with antimalarial chloroquine or hydroxychloroquine, have been repurposed to fight the current coronavirus epidemic. Exact biochemical mechanisms of these drugs towards COVID-19 have not been discovered to date.
METHODS: In-silico molecular docking can predict the mode of binding to sort out the existing chemotherapeutics having a potential affinity towards inhibition of the COVID-19 target. An attempt has been made in the present work to carry out docking analyses of 34 drugs, including antivirals and antimalarials, to explain explicitly the mode of interactions of these ligands towards the COVID-19protease target.
RESULTS: 13 compounds having good binding affinity have been predicted towards protease binding inhibition of COVID-19.
CONCLUSION: Our in silico docking results have been confirmed by current reports from clinical settings through the citation of suitable experimental in vitro data available in the published literature.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Combinatorial chemistry & high throughput screening - 24(2021), 7 vom: 31., Seite 1055-1068 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nandi, Sisir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimalarials |
|---|
| Anmerkungen: |
Date Completed 26.07.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1386207323999200824115536 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314121560 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314121560 | ||
| 003 | DE-627 | ||
| 005 | 20231225152044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1386207323999200824115536 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314121560 | ||
| 035 | |a (NLM)32838713 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nandi, Sisir |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: The novel coronavirus disease (COVID-19) is caused by a new strain (SARS-CoV-2) that erupted in 2019. Nowadays, it is a great threat that claims uncountable lives worldwide. There is no specific chemotherapeutics developed yet to combat COVID-19. Therefore, scientists have been devoted to the quest of the medicine that can cure COVID-19 | ||
| 520 | |a OBJECTIVE: Existing antivirals, such as ASC09/ritonavir, lopinavir/ritonavir with or without umifenovir in combination with antimalarial chloroquine or hydroxychloroquine, have been repurposed to fight the current coronavirus epidemic. Exact biochemical mechanisms of these drugs towards COVID-19 have not been discovered to date | ||
| 520 | |a METHODS: In-silico molecular docking can predict the mode of binding to sort out the existing chemotherapeutics having a potential affinity towards inhibition of the COVID-19 target. An attempt has been made in the present work to carry out docking analyses of 34 drugs, including antivirals and antimalarials, to explain explicitly the mode of interactions of these ligands towards the COVID-19protease target | ||
| 520 | |a RESULTS: 13 compounds having good binding affinity have been predicted towards protease binding inhibition of COVID-19 | ||
| 520 | |a CONCLUSION: Our in silico docking results have been confirmed by current reports from clinical settings through the citation of suitable experimental in vitro data available in the published literature | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a prediction of lead compounds. | |
| 650 | 4 | |a structure-based docking | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Kumar, Mohit |e verfasserin |4 aut | |
| 700 | 1 | |a Saxena, Mridula |e verfasserin |4 aut | |
| 700 | 1 | |a Saxena, Anil Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Combinatorial chemistry & high throughput screening |d 1998 |g 24(2021), 7 vom: 31., Seite 1055-1068 |w (DE-627)NLM097489352 |x 1875-5402 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:7 |g day:31 |g pages:1055-1068 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1386207323999200824115536 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 7 |b 31 |h 1055-1068 | ||